As of Wednesday close, Mersana Therapeutics Inc.’s (NASDAQ:MRSN) stock was up $0.03, moving up 2.52 percent to $1.22. The average number of shares traded per day over the past five days has been 1,758,360 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0100 gain in that time frame. In the last twenty days, the average volume was 2,220,575, while in the previous 50 days, it was 7,849,310.
Since last month, MRSN stock rose 4.27%. Shares of the company fell to $1.0200 on 08/03/23, the lowest level in the past month. A 52-week high of $9.62 was reached on 06/12/23 after having rallying from a 52-week low of $0.80. Since the beginning of this year, MRSN’s stock price has dropped by -79.18% or -$4.6400, and marked a new high 20 times. However, the stock has declined by -87.32% since its 52-week high.
MRSN stock investors should be aware that Mersana Therapeutics Inc. (MRSN) stock had its last reported insider trading activity 14 days ago on Aug 17. MISRA TUSHAR, the SVP, Chief Manuf. Officer of the company, disposed of 1,908 shares for $1.18 on Aug 17. It resulted in a $2,251 divestment by the insider. Carvajal Alejandra sold 3,944 shares at an average price of $3.89 on Apr 27. The insider now owns 20,326 shares following the transaction. On Jan 17, President & CEO Protopapas Anna sold 17,346 shares at $5.74 apiece. The transaction was valued at $99,566.
Valuation Metrics
The stock’s beta is 1.43. Besides these, the trailing price-to-sales (P/S) ratio of 3.86, the price-to-book (PB) ratio of 1.56.
Financial Health
In the three months ended June 29, Mersana Therapeutics Inc.’s quick ratio stood at 4.00, while its current ratio was 4.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.28, and the total debt-to-equity ratio was 0.28. Based on annual data, MRSN earned $230.35 million in gross profit and brought in $26.58 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -173.60%. Return on equity (ROE) for the past 12 months was -255.90%.
In Mersana Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $25.08 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. MRSN’s revenue rose 59.81% to $7.8 million during the quarter, while net income inched up to $10.65 million. While analysts expected Mersana Therapeutics Inc. to report -$0.44 quarterly earnings, the actual figure was -$0.47 per share, beating the consensus estimate by -6.80%. During the quarter, the company generated -$57.96 million in EBITDA. The liabilities of Mersana Therapeutics Inc. were 221.2 million at the end of its most recent quarter ended June 29, and its total debt was $35.11 million. The value of shareholders’ equity is $120.51 million.
Technical Picture
This quick technical analysis looks at Mersana Therapeutics Inc.’s (MRSN) price momentum. With a historical volatility rate of 34.82%, the RSI 9-day stood at 35.35% on 30 August.
With respect to its five-day moving average, the current Mersana Therapeutics Inc. price is up by +0.83% percent or $0.0100. At present, MRSN shares trade +15.09% above its 20-day simple moving average and -72.77% percent below its 100-day simple moving average. However, the stock is currently trading approximately -64.53% below its SMA50 and -82.42% below its SMA200.
Stochastic coefficient K was 31.97% and Stochastic coefficient D was 33.02%, while ATR was 0.1102. Given the Stochastic reading of 34.69% for the 14-day period, the RSI (14) reading has been calculated as 31.11%.
Analyst Ratings
Mersana Therapeutics Inc. downgraded its rating on Mersana Therapeutics Inc. (NASDAQ: MRSN) to a Neutral in a note to investors on July 28, 2023. The analysts firm previously had an Outperform rating on the stock.Mersana Therapeutics Inc. (MRSN) has been rated Hold by analysts. According to 1 brokerage firm, MRSN is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Mersana Therapeutics Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $1.50, the current consensus forecast for the stock is $1.00 – $4.00. Based on these forecasts, analysts predict Mersana Therapeutics Inc. (MRSN) will achieve an average price target of $2.00.
